Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trial watch: IDO inhibitors in cancer therapy
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 147

Showing 1-25 of 147 citing articles:

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Kai Li, Houhui Shi, Benxia Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 492
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Yan Tie, Fan Tang, Yuquan Wei, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 283
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers
François‐Xavier Danlos, Claudia Grajeda‐Iglesias, Sylvère Durand, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 3
Open Access | Times Cited: 145
Tryptophan and indole metabolism in immune regulation
Alessandra Fiore, Peter J. Murray
Current Opinion in Immunology (2021) Vol. 70, pp. 7-14
Closed Access | Times Cited: 139
Clinical cancer immunotherapy: Current progress and prospects
Chenglong Liu, Mengxuan Yang, Daizhou Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 138
Thermal immuno-nanomedicine in cancer
Zhe Yang, Di Gao, Jing Zhao, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 2, pp. 116-134
Closed Access | Times Cited: 137
Catch me if you can: how AML and its niche escape immunotherapy
Sarah Tettamanti, Alice Pievani, Andrea Biondi, et al.
Leukemia (2021) Vol. 36, Iss. 1, pp. 13-22
Open Access | Times Cited: 124
The hallmarks of cancer immune evasion
Claudia Galassi, Timothy A. Chan, Ilio Vitale, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1825-1863
Closed Access | Times Cited: 43
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Xing Kang, Harry Cheuk-Hay Lau, Jun Yu
Cell Reports Medicine (2024) Vol. 5, Iss. 4, pp. 101478-101478
Open Access | Times Cited: 35
Endothelial cells in tumor microenvironment: insights and perspectives
Patrizia Leone, Eleonora Malerba, Nicola Susca, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 23
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
Florent Peyraud, Jean‐Philippe Guégan, Lucile Vanhersecke, et al.
Med (2025) Vol. 6, Iss. 1, pp. 100546-100546
Closed Access | Times Cited: 1
Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance
C. Raman Suri, Babita Pande, Lakkakula Suhasini Sahithi, et al.
Cancer Drug Resistance (2025)
Open Access | Times Cited: 1
Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy
Xin Peng, Youe He, Jun Huang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 89
Metabolic Interdependency of Th2 Cell-Mediated Type 2 Immunity and the Tumor Microenvironment
Simon Schreiber, Christoph M. Hammers, Achim J. Kaasch, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 68
The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives
Ondřej Uher, Katerina Hadrava Vanova, David Taïeb, et al.
Endocrine Reviews (2024) Vol. 45, Iss. 4, pp. 521-552
Open Access | Times Cited: 10
Engineering nanomedicines for immunogenic eradication of cancer cells: Recent trends and synergistic approaches
Ahmed O. Elzoghby, Omar Samir, Hagar E. S. Emam, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2475-2504
Open Access | Times Cited: 9
Fueling T-cell Antitumor Immunity: Amino Acid Metabolism Revisited
Chenfeng Han, Minmin Ge, Ping‐Chih Ho, et al.
Cancer Immunology Research (2021) Vol. 9, Iss. 12, pp. 1373-1382
Open Access | Times Cited: 54
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Gabriele Antonarelli, Chiara Corti, Paolo Tarantino, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1537-1551
Open Access | Times Cited: 50
Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute Respiratory Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology
George Anderson, Annalucia Carbone, Gianluigi Mazzoccoli
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1597-1597
Open Access | Times Cited: 46
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect
Erez N. Baruch, Jingjing Wang, Jennifer A. Wargo
Cancer Immunology Research (2021) Vol. 9, Iss. 4, pp. 365-370
Open Access | Times Cited: 43
Tryptophan metabolism in brain tumors — IDO and beyond
Michael Platten, Mirco Friedrich, Derek A. Wainwright, et al.
Current Opinion in Immunology (2021) Vol. 70, pp. 57-66
Open Access | Times Cited: 40
Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer
Philippa R Kennedy, Martin Felices, Jeffrey S. Miller
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 32
Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy
Yan Li, Chen Yang, Zhicheng Liu, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 29
Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy
Ya Zhang, Zelin Hu, Jifa Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114524-114524
Closed Access | Times Cited: 28
The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy
Katarzyna Starska
Cancers (2023) Vol. 15, Iss. 6, pp. 1642-1642
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top